Dascena
48-hour sepsis prediction
San Francisco, CA, US
Develops predictive analytics software for early disease prediction and intervention.
How We Help
Problem Statement
The challenge of early disease prediction and timely intervention.
Core Technology
Machine learning diagnostic algorithm
Key Differentiators
Operates CLIA-certified laboratory (Dascena Labs, LLC)
Clinical Focus
Critical Care; Nephrology; Gastroenterology; Infectious Diseases
Company Info
- Business Model
- SaaS
- Total Funding
- 50,000,000
- Website
- dascena.com
Categories
Technologies
Clinical & IP
Clinical Validation
FDA-authorized de novo clearance. Prospective study: 75,147 patients, 39.5% mortality reduction, 32.3% LOS reduction. RCT: 58% relative mortality reduction. Published in NEJM AI and Nature Medicine.
MedStartr Index Score
?What do you think of Dascena?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.